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Educational aims
●● To illustrate the common signs of cognitive impairment and define potential associations between 
lung and cognitive dysfunction.
●● To illustrate the potential influence of cognitive deficits on the optimal progress of respiratory 
therapy.
●● To illustrate the importance of cognitive evaluation as part of a comprehensive clinical assessment 
for patients suspected of suffering cognitive impairment.
http://doi.org/10.1183/20734735.001417 Breathe | March 2017 | Volume 13 | No 1 e2
Cognitive impairment is highly prevalent in patients with COPD and demonstrates multiple 
detrimental effects on many aspects of patient state and therapeutic outcomes. It is attributed 
to several overlapping pathophysiological factors, with the most common being the low level of 
oxygen saturation due to respiratory insufficiency. Despite the impact of cognitive impairment 
on clinical outcomes, the screening for coexisting cognitive deficits which may interfere with 
the successful progress of respiratory treatment is yet neglected. There is a special consideration 
that cognitive deficits should be taken into account when developing respiratory therapy plans. 
Cognitively impaired patients are likely to require more support and have need of an individualised 
respiratory care plan which can also be beneficial for their cognitive deficits. Pulmonary rehabilitation 
as a multidisciplinary approach could be prioritised for COPD patients with cognitive impairment.
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Introduction
Chronic obstructive pulmonary disease (COPD) is 
characterised by persistent respiratory symptoms 
and airflow limitation [1]. It is a progressive condition 
which is associated with pulmonary and systemic 
inflammation with numerous extrapulmonary 
consequences such as cognitive deterioration [2]. 
In particular, the brain can be vulnerable to the 
systemic effects of COPD as several features of 
the disease may increase the risk for impaired 
cognitive function and also contribute to cognitive 
decline across the progress of disease severity and 
the ageing process [3]. Cognitive impairment is 
characterised by several common signs (table 1) 
and seems to have detrimental effects on many 
aspects of patient function, health status and 
quality of life, as well as being related to lower 
adherence to medical treatment and increased 
rates of hospitalisation and mortality in COPD [4–6].
A growing amount of evidence has demonstrated 
an association between cognitive impairment, 
a pathological condition that acts as a barrier to 
cognition, and COPD manifestation [7, 8]. Indeed, 
the prevalence estimates of cognitive impairment 
are increased in patients with COPD, indicating 
lung dysfunction as a risk factor for cognitive 
impairment even when data are adjusted for age, sex, 
smoking habits and education level [9]. The degree 
of prevalence ranges from 10 to 61% amongst 
COPD patients and seems to depend on the study 
population and the method of neuropsychological 
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assessment [7, 10]. The prevalence amongst older 
adults in the general population, as assessed in 
community samples, seems to be lower with between 
3 and 20% having cognitive deficits depending on 
the way that cognitive function is assessed [11, 12]. 
On average, 36% of patients with COPD will present 
with incidents of cognitive impairment [8], whereas 
only 12% of individuals amongst the general 
population [13] will be cognitively impaired. These 
higher prevalence estimates for cognitive impairment 
in COPD indicate an association between impaired 
lung-function and brain pathology that cannot be 
disputed. Nevertheless, defining all the complex 
pathophysiological mechanisms in COPD that may 
interfere with brain function is really challenging. 
Lung dysfunction and disease severity in COPD 
do not fully explain the development of cognitive 
impairment in COPD patients. Moreover, the typical 
profile of patients with COPD includes numerous 
of comorbidities, such as cardiovascular disease or 
diabetes or a combination thereof (so called “multi-
morbidity”), which may contribute to the genesis of 
cognitive impairment to a varying extent [14, 15]. In 
addition, the impact of disease severity (including 
comorbidities or other risk factors) can affect 
different domains of cognition variably, with some 
being unaffected while others present substantial 
impairment.
Cognition and 
neuropsychological domains
The word “cognition” is of Latin derivation but 
originally comes from the Greek verb “gignosko” 
which means to recognise, perceive and know [16]. 
Specifically, cognition is the mental action or 
intellectual process of acquiring, understanding 
and using knowledge or information, through 
thinking, experience and the senses, by which 
human behaviour can be adapted to new situations 
and/or preferences changed [17, 18]. Cognition 
involves different cognitive processes which can be 
divided into six basic neuropsychological domains 
including learning and memory, visuospatial and 
motor function, attention/concentration, language, 
social cognition/emotions and executive functions 
(figure 1). Each domain contains specific functions 
which provide individuals with basic and more 
complex capabilities that determine personal 
intellectual skills and knowledge (figure 1) [18, 19].
Assessment of cognitive 
function
Cognitive function can initially be assessed 
without complex procedures or sophisticated 
equipment. Using appropriately validated 
screening tests for cognitive impairment, 
healthcare professionals may obtain a first 
overview of the cognitive status of a patient, as 
inferred from the relationship of the patient’s 
score to reference norms. Patients with very low 
screening scores can be considered as cognitively 
impaired and may therefore be referred to a 
mental health clinic, whereas patients with 
borderline scores may be referred for further 
comprehensive assessment by a specialist with 
expertise in evaluating mental function [20]. A 
borderline score may identify patients in the first 
stages of cognitive decline, which is defined as 
mild cognitive impairment (MCI), differentiating 
patients who have worse cognitive deficits than 
those expected in normal ageing but not severe 
enough to warrant a diagnosis of dementia [21].
A wide range of tools has been developed 
for screening cognitive function. Some of them 
are freely available whereas for others a licence 
is required. These tools can be described as 
comprehensive when they cover each of the 
primary cognitive domains in cognitive function 
(figure 1) or non-comprehensive when they 
identify clinically significant levels of cognitive 
impairment across a limited spectrum of cognitive 
abilities [22]. The duration of screening ranges from 
a few minutes up to several hours in the case of a 
formal neuropsychological assessment [20]. Most 
of the tests designed for use in prompt cognitive 
evaluation during the daily clinical routine take 
Table 1 Signs of cognitive impairment: several symptoms may imply a cognitive dysfunction in patients 
with chronic obstructive pulmonary disease (COPD)
Memory loss that is unusually frequent for the age of the patient
Frequent word-finding pauses or substitutions
Frequently asking the same question or repeating the same story over and over again
Inability to recognise familiar people and places and lack of orientation
Trouble in exercising judgment and taking actions
Changes in mood or behaviour which are not conscious, isolation or misbehaviour
Trouble judging distances and seeing objects properly (not caused by poor eyesight)
Problems in completing step-by-step tasks and loss of executive function (planning, organising, 
reasoning)
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from 4 to 12 min to be completed. The most 
widely-used tests which cover multiple cognitive 
domains are the Mini Mental State Examination 
(MMSE) [23], the Addenbrooke’s Cognitive 
Examination (ACE) [24, 25], the Montreal Cognitive 
Assessment (MoCA) [26], the Clock Drawing Test 
(CDT) [27] and the Mini-Cog test [28]. In addition, 
telephone interviews have been developed for use 
in distance situations where in-person cognitive 
screening is impractical or impossible [29, 30]. 
These tests have good diagnostic accuracy [31] 
and can provide healthcare professionals with a 
prompt overview of patients' cognitive status when 
cognitive impairment is suspected.
Lung impairment and 
cognitive function
Cognitive function refers to the general competence 
of cognitive abilities that can be affected by COPD 
pathophysiology. The relationship between lung 
impairment and cognitive function decline has 
already been confirmed in numerous studies, which 
have demonstrated the particularly negative impact of 
inadequate respiratory function on cognitive domains 
such as memory and learning, attention, psychomotor 
speed, visuospatial abilities, executive functions, and 
language skills [32–34]. These negative consequences 
on cognitive function are a result of complex 
interactions amongst COPD pathophysiological, 
genetic and environmental factors.
The most obvious independent risk factor 
for cognitive impairment in patients with COPD 
is reduced oxygen availability as a result of lung 
dysfunction. From a physiological point of view it 
is reasonable to consider that the brain, which has 
almost the highest oxygen demand of any organ in 
the human body (the biggest oxygen consumers are 
the liver (20.4%), the brain (18.4%), and the heart 
(11.6%)) [35], is highly sensitive and exposed to 
ischaemic damage. If oxygen supply is insufficient 
to meet the metabolic demands of the brain 
due to impaired lung mechanics or inadequate 
respiratory function in COPD patients, this can 
trigger the loss of vulnerable cerebral neurons [36]. 
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Figure 1 Major domains of cognitive function.
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Therefore, arterial hypoxia seems to be a major 
contributor to cognitive impairment with higher 
levels of oxygen desaturation increasing the risk of 
cognitive dysfunction [37]. Moreover, lower cognitive 
performance has been found to be related to elevated 
carbon dioxide tension (PCO2) and the occurrence 
of hypercapnia at rest or during activity [38, 39]. 
Evidence has shown that increased PCO2 is related 
to lower reaction times, delayed memory, slower 
information processing speed, and deficits in 
attention and concentration [40]. Also, study data 
has demonstrated that chronic hypoxia–hypercapnia 
can negatively affect patients’ cognitive function 
including some distinctive patterns of cognitive 
dysfunction [41]. In addition, Liesker et al. [42] 
have observed that overall cognitive impairment is 
significantly worse in both hypoxaemic and non-
hypoxaemic COPD patients when compared to 
healthy individuals. Also, the overall relationship 
between PCO2 and cognitive impairment is even less 
clear when compared to low levels of oxygen. Van de 
Ven et al. [43] did not find abnormal cerebrovascular 
responses to carbon dioxide in hypercapnic patients 
with COPD and hypoxaemia or hypercapnia alone 
are not enough to entirely account for the observed 
cognitive deficits in patients with COPD. Additional 
risk factors that are not directly related to lung 
function could therefore be potential contributors 
to cognitive impairment in COPD.
Risk factors for cognitive 
impairment in COPD
Besides lower oxygen and/or higher carbon dioxide 
levels in blood, a complex interaction between 
pulmonary and non-pulmonary risk factors may 
account for COPD-related cognitive deficits [18]. 
According to the literature, other major risk factors 
which may potentially be associated with cognitive 
impairment are: 1) the presence of increased 
inflammation and oxidative stress [44, 45]; 
2) reduced physical activity [46, 47]; 3) peripheral 
vascular disease [48]; 4) high or low blood pressure 
(non-normotensive patients) [49, 50]; 5) increased 
intracranial pressure associated with the narrowing 
of blood vessels in the brain [51]; 6) coexisting 
comorbidities [52]; 7) tobacco smoking [53]; and 
8) genetic predisposition [54].
The pathophysiological mechanisms which link 
these risk factors with cognitive impairment are 
not clearly understood. It appears that there is 
a general concept that increased inflammation 
and oxidative stress, as well as the lack of physical 
activity, can express the ageing process and, 
therefore, increase age-related neurodegenerative 
changes [55]. Moreover, vascular disturbances 
leading to systemic hypertension or increased 
intracranial pressure are a risk factor for ischemic 
cortical infarcts [56]. On the other hand, systemic 
hypotension, which seems to be related to cerebral 
hypoperfusion in response to the reduced blood 
flow often caused by increased medication, may 
be responsible for protein synthesis abnormalities 
and reduced oxygen availability resulting in 
neurodegenerative lesions [57]. Moreover, reduced 
tonic cortical arousal related to hypoperfusion may 
contribute to lower cognitive performance [58]. 
Coexisting comorbidities that contribute to overall 
lung disease severity [59] and tobacco smoking, 
which appears to modulate brain function through 
nicotine [53], may also be accountable for cognitive 
dysfunction. Furthermore, genetic abnormalities 
are a major contributor to cognitive disability [60]. 
Several risk factors for cognitive deterioration, both 
with an independent impact and with overlapping 
contributions towards the development of 
cognitive impairment, are illustrated in Figure 2.
Should cognitive function 
be evaluated in the initial 
respiratory assessment?
Cognitive impairment has a negative impact on the 
personal characteristics of COPD patients including 
psychological profile, conscientiousness and the 
general ability to communicate and understand. 
The prevention of cognitive impairment by early 
intervention is thus important for treating, delaying 
or postponing its underlying processes and dealing 
with potential functional impairments that can 
act as barriers to the therapeutic management 
of COPD [61]. Specifically, cognitive deficits can 
result in an inability to accurately perform given 
instructions in respiratory examinations, such as in 
spirometry where several respiratory manoeuvres 
are included. A concerning issue then arises, as 
this could result in erroneous estimations of lung 
function capacity and potential misdiagnosis of the 
stage of disease severity in COPD [62]. Similarly, 
these patients may not understand the meaning of 
maximal exercise tests resulting in lower effort and 
underestimation of their exercise performance [63]. 
Moreover, cognitive impairment may be held 
responsible for insufficient adherence to therapeutic 
modalities and/or to medication and this is costly. 
The lack of adherence to a therapeutic strategy is 
a significant obstacle in optimal management of 
COPD and results in increased rates of morbidity, 
healthcare expenditure, and hospitalisation, as 
well as increased risk of mortality, unnecessary 
escalation of therapy and poorer quality of life [64]. 
Evidence has shown that an average of 40 to 60% 
of patients with COPD are committed to the 
prescribed regimen while only 1 in 10 patients with 
a metered-dose inhaler perform all of the essential 
steps correctly [65]. Communication problems 
and/or misunderstandings between patient and 
doctor may also result in refusal of treatment [66]. 
Forgetting or refusing to take a prescribed dose 
is usually the most frequent cause of non-
adherence [67]. Furthermore, COPD patients with 
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cognitive impairment may exhibit more functional 
dependence during a pulmonary rehabilitation 
programme and gain less benefits from it compared 
to cognitively intact counterparts [68].
Taking into account all the aforementioned 
issues, it is reasonable to conclude that cognitive 
function should be part of the initial respiratory 
assessment, especially for those patients presenting 
evident or self-reported symptoms of cognitive 
deficit, preferably corroborated by a close-informant 
[69]. Cognitive function also deserves particular 
attention in older patients (>65 yrs) at high risk, 
such as COPD patients with hypoxaemia, increased 
inflammation and coexisting comorbidities. 
Therefore, healthcare professionals who deal 
with elderly COPD patients are advised to be 
skilled in administering at least one brief cognitive 
test to a patient when cognitive impairment is 
suspected [70]. Timely detection of mild cognitive 
impairment (MCI) and awareness of this disorder 
is of great importance as actions can be taken to 
minimise or even to reverse cognitive decline and its 
consequences, and identify patients with increased 
risk of developing dementia.
Treatment of cognitive 
impairment as part of 
respiratory care
The goal of COPD management is to improve 
a patient’s functional status by preserving 
optimal lung function and to improve quality of 
life by mitigating the symptoms of disease and 
preventing secondary complications or recurrence 
of exacerbations [1]. However, the high prevalence 
of cognitive impairment in patients with COPD, in 
association with the detrimental consequences of 
cognitive deficits on functional status and quality 
of life, may indicate that action should be taken 
towards dealing with cognitive impairment within 
the frame of respiratory treatment. According to 
the literature there are some modifiable factors, 
such as physical activity [71, 72], balanced diet [73], 
cognitive training [74] and social engagement [75], 
that can be improved to provide beneficial effects to 
patients with COPD who have presented evidence 
of cognitive impairment.
Pulmonary rehabilitation as a multidimensional 
programme of exercise and education can be highly 
recommended for COPD patients with cognitive 
impairment [76]. The exercise programmes 
implemented during pulmonary rehabilitation, 
along with nutritional support, have been 
recommended as effective strategies to counteract 
neurological and cognitive disorders [77]. In 
addition, pulmonary rehabilitation provides 
patients with the opportunity to establish social 
contacts, obtain support and sympathy, and 
interact with, encourage, and motivate the other 
participants [78]. Pulmonary rehabilitation has also 
been found to reduce symptoms of depression and 
anxiety in COPD patients [79,80,81]. All these 
aforementioned favourable effects can be very 
promising for cognitively impaired patients with 
COPD. Indeed, Pereira et al. [82] have investigated 
the effects of pulmonary rehabilitation on cognitive 
function in patients with COPD and have reported 
significant improvements in cognitive performance 
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Figure 2 Determinants of cognitive impairment with potential independent and overlapping impact on cognitive function. TNF-α: tumour necrosis factor-α; 
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even after adjustment for sociodemographic 
factors. Clinical improvements in visual attention, 
verbal memory and visuospatial skills have also 
been demonstrated in cognitively impaired 
COPD patients after participating in a 3-week 
rehabilitation programme [83]. Moreover, oxygen 
therapy may ameliorate or delay the progression 
of some cognitive deficits. Karamanli et al. [84] 
have demonstrated that the global cognitive 
function of COPD patients who did not use long-
term oxygen therapy was worse compared to those 
who did. Indeed, the effect of such therapy on 
cognitive function has been found to be especially 
beneficial in hypoxaemic patients [37]. Considering 
the high prevalence of cognitive impairment, its 
consequences in patients with COPD and the 
importance of timely detection of cognitively 
impaired patients, special attention to COPD-
related cognitive impairment is needed within 
the frame of respiratory assessment. Moreover, 
the beneficial effects of pulmonary rehabilitation 
on cognitive function could be an argument for 
prioritising the attendance of COPD patients with 
cognitive deficits in a comprehensive pulmonary 
rehabilitation programme.
Conclusions
Cognitive impairment is a prevalent limitation in 
patients with COPD and cognitive deficits should 
therefore be considered prior to healthcare 
planning. It is important for healthcare professionals 
to be aware of potential cognitive deficits in patients 
with COPD that could limit the effectiveness of 
respiratory therapy. Healthcare professionals in 
respiratory settings are advised to know how to 
administer a brief cognitive assessment test to 
detect COPD-related cognitive impairments when 
required. Early detection of cognitive impairment 
can prevent or delay its underlying processes and 
minimise potential obstacles in therapeutic strategy. 
COPD patients exhibiting evidence of cognitive 
impairment should be prioritised for participation 
in a comprehensive pulmonary rehabilitation 
programme.
Educational questions
1 Regarding the impact of lung impairment on cognitive function in COPD, which of the following is true?
a) COPD patients with cognitive impairment present disadvantageous cognitive deficits in all the major cognitive domains.
b) COPD patients with cognitive impairment present profound cognitive deficits, primarily on memory ability, even though 
they are able to provide detailed examples of forgetfulness.
c) COPD patients developing cognitive impairment present cognitive deficits in at least one cognitive domain, whilst the 
rest of the domains can be unaffected.
d) COPD patients developing cognitive impairment may only occasionally present cognitive deficits in several cognitive 
domains.
2 What is the major problem related to cognitive impairment in respiratory assessment?
a) Patients’ forgetfulness and inability to understand instructions for the ongoing management of their disease may cause 
delays and act as a barrier to therapeutic management.
b) Communication problems or memory deficits due to cognitive impairment may result in misleading information being 
provided to healthcare professionals by patients.
c) Communication problems between patients and healthcare professionals may limit the application of important tests 
during respiratory assessment.
d) Patients’ inability to accurately perform respiratory manoeuvres and their lack of effort in stress tests may result in 
erroneous estimations of the progress of disease severity.
3 Why is early detection of cognitive impairment within the respiratory assessment important?
a) Because it averts or addresses potential safety issues.
b) Because there are certain modifiable factors (i.e. physical activity, cognitive training and social engagement) that can be 
improved, presenting beneficial effects on cognitive impairment.
c) Because it ensures that patients will have a caregiver or someone else to help them with their medical treatment.
d) Because it allows healthcare professionals to plan long-term treatment and care.
4 Why can pulmonary rehabilitation (PR) be beneficial to cognitive impairment in COPD?
a) Because exercise training may counteract neurological and cognitive disorders.
b) Because patients establish social contacts, obtain support and reduce anxiety/depression, and these factors have 
favourable effects on cognitive impairment.
c) Because clinical improvement has been reported in visual attention, verbal memory and visuospatial skills even after a 
short-term PR program (3 weeks).
d) Because of all of the above.
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